Stockscreener 앱 받기
0.9301
1.03%
-0.0097
전일 마감가:
$0.9398
열려 있는:
$0.94
하루 거래량:
40,078
Relative Volume:
0.14
시가총액:
$41.95M
수익:
$1.12M
순이익/손실:
$-11.17M
주가수익비율:
-2.9424
EPS:
-0.3161
순현금흐름:
$-10.98M
1주 성능:
+1.09%
1개월 성능:
+9.33%
6개월 성능:
-16.96%
1년 성능:
-30.59%
1일 변동 폭
$0.9013
$0.94
1주일 범위
$0.89
$0.96
52주 변동 폭
$0.7006
$1.45
Renovorx Inc Stock (RNXT) Company Profile
명칭
Renovorx Inc
전화
408-800-2649
주소
2570 W. EL CAMINO REAL, STE. 320,, MOUNTAIN VIEW
Compare RNXT vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
RNXT
Renovorx Inc
|
0.9301 | 41.95M | 1.12M | -11.17M | -10.98M | -0.3161 |
VRTX
Vertex Pharmaceuticals Inc
|
485.39 | 123.19B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
664.52 | 69.67B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.62 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
298.76 | 39.89B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
186.88 | 39.73B | 742.00K | -1.37B | -1.07B | -7.0731 |
Renovorx Inc 주식(RNXT)의 최신 뉴스
RNXTRenovoRx Inc Latest SEC Filings - Finviz
RenovoRx Granted Extended Nasdaq Compliance Period Amid Listing Risk - The Globe and Mail
RenovoRx Receives Nasdaq Delisting Notice: Key Details from Latest 8-K Filing - Minichart
RenovoRx Received Notice of Noncompliance - TradingView
RenovoRx Stockholders Approve Directors and Equity Plan - The Globe and Mail
Nasdaq grants RenovoRx (RNXT) new deadline to fix $1 bid price - Stock Titan
RenovoRx, Inc. Financial Disclosures & SEC Filings - TradingView
RenovoRx 2021 Omnibus Equity Incentive Plan Amended: Key Vote Results and SEC Filing Details (June 2026) - Minichart
RenovoRx (RNXT) investors approve directors, expand equity plan and ratify 2026 auditor - Stock Titan
RenovoRx (RNXT) Edges Higher, Testing Key Resistance at $1.02Advance Decline Line - dars.gov.et
Enterprise value to revenue forward of RenovoRx, Inc. – NASDAQ:RNXT - TradingView
Enterprise value to EBITDA forward of RenovoRx, Inc. – NASDAQ:RNXT - TradingView
Price to book forward of RenovoRx, Inc. – NASDAQ:RNXT - TradingView
RNXT Forecast — Price Target — Prediction for 2027 - TradingView
RenovoRx Inc (RNXT) Valuation: PE, PB & Fair Value Analysis - TradingKey
RenovoRx, Inc. Actuals & Estimates (NASDAQ:RNXT) - TradingView
Form 4 RenovoRx Inc For: 24 June By Investing.com - Investing.com Nigeria
RenovoRx (RNXT) director reorganizes indirect share holdings via trust - Stock Titan
RNXT: Strong commercial growth and clinical data position the therapy for major impact in cancer care - TradingView
RNXT: Strong commercial growth and clinical data position the platform for expanded cancer therapy adoption - TradingView
RenovoRx (RNXT) Stock Price, News & Analysis - MarketBeat
RenovoRx, Inc. (RNXT) reports Q1 loss, tops revenue estimates - MSN
RenovoRx Inc (RNXT) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
RenovoRx Inc (RNXT) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
RenovoRx Inc (RNXT) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
RenovoRx Inc (RNXT) Institutional Confidence - TradingKey
RenovoRx Inc (RNXT) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
RenovoRx Inc (RNXT) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
RenovoRx Inc (RNXT) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
RenovoRx Inc (RNXT) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
RNXT Q1 2026 Earnings: EPS Misses Estimates as Pre‑Revenue Biotech Advances Clinical ProgramsAnalyst Consensus Shift - newsline.com
RNXT News | RENOVORX INC (NASDAQ:RNXT) - ChartMill
RenovoRx Highlights Peer-Reviewed Publication Supporting Intra-Arterial Gemcitabine Delivery Via TAMP in Locally Advanced Pancreatic Cancer - Investing News Network
RenovoRx Highlights Peer-Reviewed Publication Supporting Intra-Arterial Gemcitabine Delivery Via TAMP™ in Locally Advanced Pancreatic Cancer - The Manila Times
Targeted artery chemo saw 52% tumor activity drop in pancreatic cancer case - Stock Titan
RenovoRx (RNXT) Q1 2026 Earnings: EPS Falls Short of Estimates as Pre-Revenue Biotech Advances Clinical PipelineGuidance Update - newsline.com
RNXT Q1 2026 Earnings: EPS Misses Estimates as Pre-Revenue Oncology Firm Advances Clinical PipelineEarnings Whisper Number - newsline.com
RenovoRx Inc. (RNXT) Holds Steady Near Support as Investors Eye ResistanceInstitutional Flow Picks - newsline.com
RNXT Q1 2026 Earnings: EPS Miss Widens Losses as Stock Declines 10.6%Post-Earnings Drift - newsline.com
RenovoRx CEO, Shaun Bagai, to Present at the iAccess Alpha Virtual Best Ideas Summer Investment Conference 2026 on June 23rd - Investing News Network
RNXT Q1 2026 Earnings: EPS Misses Estimates as Pre-Revenue Biotech Advances Clinical PipelinePre-Announcement Alert - newsline.com
Stock Ratings | Raymond James raised its target price for Micron (MU) to $1,100; Ascendiant raised its target price for RenovoRx (RNXT) to $14, indicating a potential upside of 1,420.58% - Sahm
RNXT Maintains Buy Rating by Ascendiant Capital -- Price Target Raised to $14.00 - GuruFocus
RenovoRx Inc. (RNXT) Q1 2026 Earnings: Loss per share misses estimates as stock declinesEBITDA Estimate Trend - dars.gov.et
New chemotherapy delivery method scores FDA orphan drug status - Rare Cancer News
RNXT Q1 2026 Earnings: EPS Misses Estimates as Clinical-Stage Biotech Advances TrialsEarnings Preview - The Legal Advocate
RenovoRx Inc. (RNXT) Moves Higher by 6.2% as Shares Approach Resistance at $1.04Volatility Term Structure - The Legal Advocate
RenovoRx (RNXT) Advances 6.2% as Momentum Builds Toward ResistanceCall Spread Alert - The Legal Advocate
RenovoRx receives FDA orphan drug designation for oxaliplatin - Investing.com UK
RenovoRx Announces FDA Orphan Drug Designation Granted: Oxaliplatin for the Treatment of Pancreatic Cancer - Investing News Network
RenovoRx receives FDA orphan drug designation for oxaliplatin By Investing.com - Investing.com Australia
Renovorx Inc (RNXT) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.64%
자본화:
|
볼륨(24시간):